Digital Diagnostics

Digital Diagnostics is a trailblazer in the field of AI healthcare, being the first company to receive FDA clearance for an AI diagnostic platform that makes a diagnosis without physician input. Their flagship product, LumineticsCore™, autonomously diagnoses diabetic retinopathy, including macular edema, at the point-of-care. This system, which has been trained and validated on over 2 million images, ensures equitable performance across all demographics, mitigating bias related to sex, race, or ethnicity. LumineticsCore™ is integrated into the American Diabetes Association’s Standard of Diabetes care and has significantly reduced unnecessary specialty visits by providing accurate diagnostic results at the point-of-care. Digital Diagnostics is committed to transforming healthcare affordability, accessibility, and quality through the automation of medical diagnosis and treatment, with a strong focus on ethical AI, safety, efficacy, and equity. The company also explores extending dermatological care beyond the exam room, addressing conditions such as acne, eczema, and skin cancers. Digital Diagnostics has established the first autonomous AI CPT® category 1 code for billing and payment and offers a product training platform to help users gain expertise in their AI diagnostic systems. Their centralized Independent Diagnostic Testing Facility (IDTF) is located in Austin, TX. The company’s products are designed to integrate seamlessly into clinical workflows, ensuring efficient and effective diagnostic results at the point-of-care.